R. L. Waite

发表

Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

William B. Downs, K. Blum, D. Barh, 2013, Journal of addiction research & therapy.

Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™

Margaret A. Madigan, K. Blum, D. Barh, 2013, Journal of genetic syndromes & gene therapy.

A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain

Margaret A. Madigan, K. Blum, D. Barh, 2014, Journal of genetic syndromes & gene therapy.

Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

William B. Downs, K. Blum, D. Barh, 2012, Journal of addiction research & therapy.

Kenneth Blum 1,5,6,8,10,11,12,15*, Marlene Oscar-Berman2, Elizabeth Stuller3, David Miller4,5, John Giordano6, Siobhan Morse6, Lee McCormick7, William Downs B5, Roger L Waite5, Debmalya Barh8, Dennis Neal9, Eric R Braverman1,10, Raquel Lohmann10, Joan Borsten11, Mary Hauser12, David Han13, Yijun Liu

K. Blum, D. Barh, M. Oscar-Berman, 2012 .

Overcoming qEEG Abnormalities and Reward Gene Deficits during Protracted Abstinence in Male Psychostimulant and Polydrug Abusers Utilizing Putative Dopamine D2 Agonist Therapy: Part 2

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2010, Postgraduate medicine.

Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.

Thomas J. H. Chen, B. Meshkin, K. Blum, 2007, Medical hypotheses.

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence

K. Blum, M. Febo, Z. Demetrovics, 2016, Clinical medical reviews and case reports.

NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Religiosity

Margaret A. Madigan, K. Blum, M. Oscar-Berman, 2015, Journal of reward deficiency syndrome.

Can Genetic Testing Coupled with Enhanced Dopaminergic Activation Reduce Recidivism Rates in the Workers Compensation Legacy Cases?

Margaret A. Madigan, K. Blum, D. Barh, 2014, Journal of alcoholism and drug dependence.

Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART)

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2009, Postgraduate medicine.

Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen: Proposing an Addiction Candidate Gene Panel Map

William B. Downs, Thomas J. H. Chen, K. Blum, 2011, Journal of psychoactive drugs.

LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

Thomas J. H. Chen, K. Blum, T. Palomo, 2008, Advances in therapy.

Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands

L. D. White, Thomas J. H. Chen, K. Blum, 2008 .

Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.

Thomas J. H. Chen, K. Blum, M. Oscar-Berman, 2009, Medical hypotheses.

A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics

William B. Downs, Thomas J. H. Chen, K. Blum, 2008 .

GENETIC ADDICTION RISK SCORE (GARS) ANALYSIS: EXPLORATORY DEVELOPMENT OF POLYMORPHIC RISK ALLELES IN POLY-DRUG ADDICTED MALES

Margaret A. Madigan, K. Blum, M. Kerner, 2010 .

Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2010, Current neuropharmacology.

Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).

Margaret A. Madigan, Kenneth Blum, Thomas J. H. Chen, 2010, Medical hypotheses.

Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.

Margaret A. Madigan, Thomas J. H. Chen, D. Comings, 2011, International journal of environmental research and public health.

Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Should Reward Gene Polymorphisms Constitute a Diagnostic Tool to Identify Individuals at Risk for Impaired Judgment?

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2012, Molecular Neurobiology.

Genetic Addiction Risk Score (GARS): Testing For Polygenetic Predisposition and Risk to Reward Deficiency Syndrome (RDS)

K. Blum, F. Fornari, E. Braverman, 2011 .

Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender

Thomas J. H. Chen, K. Blum, E. Braverman, 2009 .

THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS.

K. Blum, R. Badgaiyan, E. Braverman, 2016, Precision medicine.

Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?

Thomas J. H. Chen, K. Blum, M. Oscar-Berman, 2009, Medical hypotheses.

Attention-de fi cit-hyperactivity disorder and reward de fi ciency syndrome

Thomas J. H. Chen, D. Comings, K. Blum, 2008 .

Attention-deficit-hyperactivity disorder and reward deficiency syndrome

Thomas J Prihoda, Kenneth Blum, Thomas J. H. Chen, 2008, Neuropsychiatric disease and treatment.

Hypothesizing “Reward” Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: A Nutrient and Electrotherapeutic Based Solution

Margaret A. Madigan, K. Blum, E. Braverman, 2014 .

Attention-defi cit-hyperactivity disorder and reward defi ciency syndrome

Thomas J. H. Chen, D. Comings, K. Blum, 2008 .

Autoantibodies to a novel early endosome antigen 1.

H. Stenmark, B. Toh, R. Waite, 1998, Clinical immunology and immunopathology.

Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects

Thomas J. H. Chen, K. Blum, E. Braverman, 2009 .

Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary

Thomas J. H. Chen, D. Comings, K. Blum, 2008, Theoretical Biology and Medical Modelling.

Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2010, Medical hypotheses.

Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART)

Margaret A. Madigan, Thomas J. H. Chen, K. Blum, 2009, Postgraduate medicine.

Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors

Margaret A. Madigan, Thomas J. H. Chen, D. Comings, 2011, International journal of environmental research and public health.

UNDERSTANDING THE HIGH MIND: HUMANS ARE STILL EVOLVING GENETICALLY

William B. Downs, Margaret A. Madigan, K. Blum, 2011 .

Preliminary association of both the Dopamine D2 Receptor (DRD2) (Taq1 A1 Allele) and the Dopamine Transporter (DAT1) (480 bp Allele) genes with pathological aggressive behavior, a clinical subtype of Reward Deficiency Syndrome (RDS) in adolescents

Thomas J. H. Chen, D. Comings, B. Meshkin, 2007 .

Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia

Kenneth Blum, Uma Damle, Thomas J. H. Chen, 2010, Neuropsychiatric disease and treatment.

Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study

L. D. White, Thomas J. H. Chen, D. Comings, 2007 .

Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome

Thomas J. H. Chen, B. Meshkin, K. Blum, 2007, Advances in therapy.

Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications

Debmalya Barh, Kenneth Blum, K. Blum, 2015, Journal of addiction research & therapy.

Clinical Medical Reviews and Case Reports Neurobiology of Kb220z-glutaminergic-dopaminergic Optimization Complex [gdoc] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input following Chronic Intake

K. Blum, M. Febo, R. Badgaiyan, 2022 .

Theoretical Biology and Medical Modelling Activation Instead of Blocking Mesolimbic Dopaminergic Reward Circuitry Is a Preferred Modality in the Long Term Treatment of Reward Deficiency Syndrome (rds): a Commentary

Edu, Thomas J. H. Chen, D. Comings, 2022 .

Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study

William B. Downs, Margaret A. Madigan, Thomas J. H. Chen, 2012, Journal of psychoactive drugs.

Audio Therapy Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans

Margaret A. Madigan, K. Blum, D. Barh, 2013 .

Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment : Putative Activation of Dopaminergic Pathways in the MesoLimbic Reward Circuitry of Humans

Margaret A. Madigan, K. Blum, D. Barh, 2011 .

LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome

Thomas J. H. Chen, K. Blum, E. Braverman, 2008, Advances in therapy.

Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse

Margaret A. Madigan, K. Blum, D. Barh, 2011 .

Neuroquantum Theories of Psychiatric Genetics: Can Physical Forces Induce Epigenetic Influence on Future Genomes?

K. Blum, M. Febo, T. Archer, 2015 .

Invited Commentary: In a Genomic Era, Should We Promote Dopamine Homeostasis to Treat Opiate/ Opioid Abuse, Instead of Blocking Brain Dopamine Function?

K. Blum, M. Febo, R. Badgaiyan, 2017 .

Hypothesizing repetitive paraphilia behavior of a medication refractive Tourette's syndrome patient having rapid clinical attenuation with KB220Z-nutrigenomic amino-acid therapy (NAAT).

William B. Downs, Margaret A. Madigan, K. Blum, 2013, Journal of behavioral addictions.

Health economics of nutrigenomics in weight management

Thomas J. H. Chen, B. Meshkin, K. Blum, 2008 .

Repetitive H-Wave® device stimulation and program induces significant increases in the range of motion of post operative rotator cuff reconstruction in a double-blinded randomized placebo controlled human study

Thomas J. H. Chen, K. Blum, E. Braverman, 2009, BMC musculoskeletal disorders.

H‐Wave® induces arteriolar vasodilation in rat striated muscle via nitric oxide‐mediated mechanisms

Thomas J. H. Chen, K. Blum, N. Dinubile, 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis

Thomas J. H. Chen, K. Blum, E. Braverman, 2008, Advances in therapy.

The H-Wave® small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study

Thomas J. H. Chen, B. Meshkin, K. Blum, 2006, Advances in therapy.

H-wave®, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: A preliminary statistical outcome study

Thomas L. Smith, Thomas J. H. Chen, B. Meshkin, 2006, Advances in therapy.